Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
Amazon Reviews Supplier Costs as U.S.–China Tariffs Ease 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
BlueScope Steel Announces A$1 Special Dividend After Asset Sales 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
BRISBANE, Calif., March 30, 2017 -- KaloBios Pharmaceuticals, Inc. (OTC:KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, announced that Cameron Durrant, MD, chairman and CEO, will be a speaker and panelist during the International Society for Neglected Tropical Diseases (ISNTD) Chagas conference.
ISNTD Chagas will take place on Thursday, April 6, 2017, at the Kimpton Hotel Palomar in Washington, D.C.
Dr. Durrant will join Jeffrey Moe, PhD, of the Duke Global Health Institute, Anne Marie Finley of the Biotech Policy Group, and Cecilia Inés Centurión of the Chagas Disease Alliance in a session to discuss how public policy can support the development of medicines for neglected tropical diseases.
“Chagas is a neglected tropical disease in the U.S. affecting approximately 300,000 underserved people, and the inaugural ISNTD Chagas conference will bring together experts and stakeholders from across the spectrum in a groundbreaking gathering in our nation’s capital,” said Dr. Durrant. “Chagas needs more attention, and with the necessary ingredients of dedicated stakeholders, enlightened public policy and patient care including approved medicines, we can hopefully make a difference. We look forward to building collaborative dialogue and understanding to improve the foundation from which to help these neglected patients.”
ISNTD Chagas aims to bring together the Chagas R&D community, patient advocates, civic groups, and policymakers to further efforts to combat this neglected global health issue. For more information about the conference, please visit www.isntdchagas.com.
About KaloBios Pharmaceuticals, Inc.
KaloBios Pharmaceuticals, Inc. (OTC:KBIO) is an emerging biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases through innovative and responsible business models. Lead compounds in the KaloBios portfolio are benznidazole for the potential treatment of Chagas disease in the U.S., and the proprietary monoclonal antibodies, lenzilumab and ifabotuzumab (formerly KB004), for the potential treatment of various solid and hematologic cancers such as chronic myelomonocytic leukemia (CMML) and potentially juvenile myelomonocytic leukemia (JMML). For more information, visit www.kalobios.com.
CONTACT: Investors: Mike Cole O: 949-259-4988 C: 949-444-1341 [email protected] Media: Lisa Guiterman O: 301-217-9353 C: 202-330-3431 [email protected]
